Why Predicitive Oncology Stock Is Soaring
Why Predicitive Oncology Stock Is Soaring
"We have already demonstrated the capabilities of our active machine learning platform to selectively utilize our diverse patient samples preserved in our biobank to predict responses to drugs with a very high degree of accuracy," said Predictive Oncology Inc. (NASDAQ:POAI) shares are blasting higher Thursday after the company announced it is expanding its AI and machine learning driven drug discovery platform to pursue discovery of novel biomarkers.
Predictive Oncology Inc.（納斯達克股票代碼：POAI）週四股價上漲，此前該公司宣佈將擴大其人工智能和機器學習驅動的藥物發現平台，以探索新型生物標誌物。
The Details:
細節：
Predictive Oncology said its latest biomarker discovery initiative stems, in part, from results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital. In that study, Predictive Oncology successfully developed muti-omic machine learning models that identified key features that could more accurately predict both short-term and long-term survival outcomes among ovarian cancer patients as compared to clinical data alone.
Predictive Oncology表示，其最新的生物標誌物發現計劃在一定程度上源於UPMC Magee-Womens Hospital的回顧性卵巢癌研究的結果。在該研究中，Predictive Oncology成功開發了多組學機器學習模型，該模型確定了關鍵特徵，與單獨的臨床數據相比，這些特徵可以更準確地預測卵巢癌患者的短期和長期存活結果。
"We have already demonstrated the capabilities of our active machine learning platform to selectively utilize our diverse patient samples preserved in our biobank to predict responses to drugs with a very high degree of accuracy," said Arlette H. Uihlein, MD, SVP, medical director at Predictive Oncology.
Predictive Oncology醫學總監、高級副總裁、醫學總監Arlette H. Uihlein表示：“我們已經證明了主動機器學習平台能夠選擇性地利用保存在生物庫中的各種患者樣本，以非常高的精度預測對藥物的反應。”
"We are now taking this one step further by applying state-of-the-art deep learning approaches for biomarker discovery related to both patient overall survival (OS) and drug response, which can be done with existing resources. Our platform enables us to apply deep learning to the correct patient cohorts and accelerate the initial stages of biomarker discovery."
“我們現在更進一步，應用最先進的深度學習方法來發現與患者總存活率（OS）和藥物反應相關的生物標誌物，這可以利用現有資源來完成。我們的平台使我們能夠將深度學習應用於正確的患者群組，並加快生物標誌物發現的初始階段。”
According to data from Benzinga Pro, Predictive Oncology shares are trading on heavy volume Thursday and reached an intraday high of $2.96 per share.
根據Benzinga Pro的數據，Predictive Oncology的股票週四交易量很大，盤中達到每股2.96美元的高點。
Should I Sell My POAI Stock?
我應該賣出我的 POAI 股票嗎？
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
在決定持有或出售股票時，投資者應考慮其時間範圍、未實現收益和總回報。
Shares of Predictive Oncology have decreased by 50.57% in the past year. The stock has risen 63% over the past month.
在過去的一年中，預測腫瘤學的份額下降了50.57％。該股在過去一個月中上漲了63％。
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Predictive Oncology stock currently has an RSI of 46.66, indicating neutral conditions.
投資者也可以考慮市場動態。相對強弱指數可用於表明股票是超買還是超賣。預測腫瘤學股票目前的相對強弱指數爲46.66，表明狀況中性。
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
要訪問高級製圖和分析工具以及股票數據，請查看 Benzinga PRO。免費試用。
POAI Price Action: According to Benzinga Pro, Predictive Oncology shares are up 64.4% at $1.75 at the time of publication Thursday.
POAI價格走勢：根據Benzinga Pro的數據，預測腫瘤學股價在週四發佈時上漲了64.4％，至1.75美元。
Read Also:
另請閱讀：
- Viking Therapeutics Stock Climbs On Q2 EPS Beat
- Viking Therapeutics股票在第二季度每股收益上漲後上漲
Image: Shutterstock
圖片：Shutterstock